Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
NCT06604520
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are: Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD? Do mood symptoms and cognition improve following treatment with vortioxetine? Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Fronto-temporal Dementia
- Fronto-temporal Lobar Dementia
- Frontotemporal Degeneration
- Frontotemporal Dementia (FTD)
- Frontotemporal Dementia, Behavioral Variant
- Frontotemporal Dementia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Johns Hopkins University
- Last updated on ClinicalTrials.gov
- March 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- The Johns Hopkins Hospital · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.